ARMS
Conditions
Interventions
Sponsors
Eiro Tsuyoshi
Takahashi Takuya
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: We will target cases that meet all the following conditions. 1 High risk cases of psychosis that meet criteria using SIPS (Structured Interview for Prodrome Syndromes) / SOPS (The Scale of Prodromism Symptoms) 2 Men and women between 16 and 40 years old at registration 3 Patients over 20 years of age who gave written informed consent to participate in this study; under 20 years of age, informed consent was obtained for involved in this research from himself / her parents Case 4 Patients in which the patient's consent judgment ability is judged to be sufficient by the evaluation by the MacArthur Competence Assessment Tool (MacCAT)
Exclusion criteria
Exclusion criteria: It will be excluded if any of the following conditions apply. 1 During pregnancy, nursing or wishing to be pregnant(For premenopausal women,blood hCG is measured by blood sampling and confirmed to be less than 6 mIU / ml) 2 Sensitive to alcohol 3 Combination of serious neurologic diseases (neurodegenerative diseases, cases of cerebral hemorrhage and cerebral infarction which are not slight in the image before this study participation) 4 History of epilepsy 5 Take Perranpanel, Topiramate, antipsychotic medication within 4 weeks before registration 6 Substance-related disorders within 6 months (except for nicotine and caffeine) 7 Dependent substances positive by urine screening (except those who are positive for the medicine being taken for treatment) 8 Implantation of metal substances and pacemakers 9 head, neck and body size not suitable for MRI scanner 10 A tattoo larger than one point (including tattoo and art makeup) 11 Advanced claustrophobic 12 A remarkable variant of brain structure (including congenital and traumatic) 13 At the time of registration, any of the following laboratory test value abnormalities Serum creatinine 1.5 mg / dl or more AST 150 IU / L or more ALT 150 IU / L or more 14 Participating in unapproved nuclear medicine clinical trials and clinical trials within 6 months prior to enrollment 15 Participating in other trials or clinical trials within 12 weeks prior to enrollment (limited to those with invasiveness / intervention) 16 Patients judged as inappropriate for study by the research investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AMPA receptor density in the brain obtained from the first PET imaging of subjects who did and did not develop psychosis during the follow-up period | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Correlation between the AMPA receptor density in the brain and the time to onset of the examinee who developed psychosis during the follow-up period. 2) The rate of change in AMPA receptor density in the brain obtained from the first and second PET imaging in subjects who develop psychosis during the follow-up period,and correlation with the rate of change of each symptom rating scale from the PET imaging to the onset of psychosis. 3) Adverse events up to 7 days after [11C] K-2 administration. | — |
Contacts
Public ContactTsuyoshi Eiro
Yokohama City University, School of Medicine
Outcome results
None listed